Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 470-478

  Özkaya Şahin, Gülşen ^a   Månsson, Fredrik ^b   Palm, Angelica A ^c   Vincic, Elzbieta ^a   Da Silva, Zacarias ^d   Medstrand, Patrik ^b   Norrgren, Hans ^b   Fenyö, Eva Maria ^a   Jansson, Marianne ^a,e  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS RNA;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; VIRUS CONCENTRATION; VIRUS CULTURE; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADULT; ANTIBODIES, NEUTRALIZING; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNOGLOBULIN A; NEUTRALIZATION TESTS; PLASMA; VIRAL PLAQUE ASSAY; YOUNG ADULT;

EID: 84874475177     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0219     Document Type: Article

References (56)

1. Cao Y, Qin L, Zhang L, et al.: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332(4): 201-208.
2. Bello G, Velasco-de-Castro CA, Bongertz V, et al.: Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J Med Virol 2009;81(10):1681-1690.
3. Martinez-Steele E, Awasana AA, Corrah T, et al.: Is HIV-2-induced AIDS different from HIV-1-Associated AIDS? Data from a West African clinic. AIDS 2007;21(3):317-324.
4. van der Loeff MF, Larke N, Kaye S, et al.: Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010;7:46.
5. Kanki PJ, Travers KU, S MB, et al.: Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343(8903):943-946.
6. Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al.: Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994;272(6): 462-466.
7. Esbjornsson J, Mansson F, Kvist A, et al.: Natural inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012;367:224-232.
8. Simon F, Matheron S, Tamalet C, et al.: Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7(11):1411-1417.
9. Andersson S, Norrgren H, da Silva Z, et al.: Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: Significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000;160(21):3286-3293.
10. Ariyoshi K, Berry N, Wilkins A, et al.: A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa. J Infect Dis 1996;173(1): 245-248.
11. MacNeil A, Sarr AD, Sankale JL, et al.: Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007;81(10):5325-5330.
12. Endres MJ, Clapham PR, Marsh M, et al.: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87(4):745-756.
13. Shi Y, Brandin E, Vincic E, et al.: Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 2005;86(12):3385-3396.
14. Ozkaya Sahin G, Holmgren B, da Silva Z, et al.: Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol 2012; 86(2):961-971.
15. Kozlowski PA, Chen D, Eldridge JH, and Jackson S: Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res Hum Retroviruses 1994;10(7):813-822.
16. Mestecky J, Jackson S, Moldoveanu Z, et al.: Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004;20(9):972-988.
17. Israel ZR and Marx PA: Nonclassical mucosal antibodies predominate in genital secretions of HIV-1 infected chimpanzees. J Med Primatol 1995;24(2):53-60.
18. Schafer F, Kewenig S, Stolte N, et al.: Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques. Gut 2002;50(5): 608-614.
19. Lizeng Q, Skott P, Sourial S, et al.: Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 2003;308(2):225-232.
20. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4 + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200(6): 749-759.
21. Woof JM and Kerr MA: The function of immunoglobulin A in immunity. J Pathol 2006;208(2):270-282.
22. Macpherson AJ, Geuking MB, Slack E, et al.: The habitat, double life, citizenship, and forgetfulness of IgA. Immunol Rev 2012;245(1):132-146.
23. Quesnel A, Moja P, Lucht F, et al.: Is there IgA of gut mucosal origin in the serum of HIV1 infected patients? Gut 1994;35(6):803-808.
24. Mei HE, Yoshida T, Sime W, et al.: Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 2009;113(11):2461-2469.
25. van Vlasselaer P, Punnonen J, and de Vries JE: Transforming growth factor-beta directs IgA switching in human B cells. J Immunol 1992;148(7):2062-2067.
26. Boehm MK, Woof JM, Kerr MA, and Perkins SJ: The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: A study by X-ray and neutron solution scattering and homology modelling. J Mol Biol 1999;286(5): 1421-1447.
27. Kerr MA: The structure and function of human IgA. Biochem J 1990;271(2):285-296.
28. Imai H, Chen A, Wyatt RJ, and Rifai A: Lack of complement activation by human IgA immune complexes. Clin Exp Immunol 1988;73(3):479-483.
29. Wilton JM: Suppression by IgA of IgG-mediated phagocytosis by human polymorphonuclear leucocytes. Clin Exp Immunol 1978;34(3):423-428.
30. Gueudin M, Damond F, Braun J, et al.: Differences in proviral DNA load between HIV-1- and HIV-2-infected patients. AIDS 2008;22(2):211-215.
31. Damond F, Gueudin M, Pueyo S, et al.: Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J Clin Microbiol 2002;40(10):3654-3659.
32. Ozkaya Sahin G, Bowles EJ, Parker J, et al.: Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog 2010;6(9):e1001084.
33. HIV type 1 variation in World Health Organizationsponsored vaccine evaluation sites: Genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994; 10(11):1327-1343.
34. Morner A, Bjorndal A, Albert J, et al.: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999;73(3):2343-2349.
35. Albert J, Bottiger B, Biberfeld G, and Fenyo EM: Replicative and cytopathic characteristics of HIV-2 and severity of infection. Lancet 1989;1(8642):852-853.
36. Bjorndal A, Deng H, Jansson M, et al.: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71(10): 7478-7487.
37. Lauren A, Thorstensson R, and Fenyo EM: Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): The kinetics of evolution to neutralization resistance are related to progression rate of disease. J Gen Virol 2006;87(3):595-606.
38. Simek MD, Rida W, Priddy FH, et al.: Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009;83(14):7337-7348.
39. de Silva TI, Aasa-Chapman M, Cotten M, et al.: Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 2012;86(2):930-946.
40. Kong R, Li H, Bibollet-Ruche F, et al.: Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 2012;86(2):947-960.
41. Burrer R, Salmon-Ceron D, Richert S, et al.: Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIVinfected patients. J Virol 2001;75(11):5421-5424.
42. Bjorling E, Scarlatti G, von Gegerfelt A, et al.: Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993;193(1):528-530.
43. Haas A, Zimmermann K, and Oxenius A: Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol 2011;85(23):12102-12113.
44. Moir S and Fauci AS: B cells in HIV infection and disease. Nat Rev Immunol 2009;9(4):235-245.
45. Lane HC, Masur H, Edgar LC, et al.: Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309(8):453-458.
46. Leligdowicz A, Feldmann J, Jaye A, et al.: Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis 2010;201(1):114-122.
47. Chollet-Martin S, Simon F, Matheron S, et al.: Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS 1994;8(7):879-884.
48. Ferre AL, Hunt PW, Critchfield JW, et al.: Mucosal immune responses to HIV-1 in elite controllers: A potential correlate of immune control. Blood 2009;113(17):3978-3989.
49. Levesque MC, Moody MA, Hwang KK, et al.: Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009;6(7):e1000107.
50. Ciccone EJ, Greenwald JH, Lee PI, et al.: CD4 + T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J Virol 2011;85(12):5880-5888.
51. Planque S, Salas M, Mitsuda Y, et al.: Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010;24(6):875-884.
52. Pasquier B, Launay P, Kanamaru Y, et al.: Identification of FcalphaRI as an inhibitory receptor that controls inflammation: Dual role of FcRgamma ITAM. Immunity 2005;22(1):31-42.
53. Monteiro RC: The role of IgA and IgA Fc receptors as antiinflammatory agents. J Clin Immunol 2010;30(Suppl 1):S61-64.
54. Van Epps DE and Williams RC Jr: Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med 1976;144(5):1227-1242.
55. Wolf HM, Fischer MB, Puhringer H, et al.: Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-Alpha, interleukin-6) in human monocytes. Blood 1994;83(5):1278-1288.
56. Wolf HM, Hauber I, Gulle H, et al.: Anti-inflammatory properties of human serum IgA: Induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-Alpha (TNF-Alpha) and IL-6 in human monocytes. Clin Exp Immunol 1996;105(3):537-543.